Your browser doesn't support javascript.
loading
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
Plesner, Torben; Arkenau, Hendrik-Tobias; Gay, Francesca; Minnema, Monique C; Boccadoro, Mario; Moreau, Philippe; Cavenagh, Jamie; Perrot, Aurore; Laubach, Jacob P; Krejcik, Jakub; Ahmadi, Tahamtan; de Boer, Carla; Chen, Diana; Chiu, Christopher; Schecter, Jordan M; Richardson, Paul G.
Afiliação
  • Plesner T; Vejle Hospital and University of Southern Denmark, Vejle, Denmark.
  • Arkenau HT; Sarah Cannon Research Institute, University College London Cancer Institute, London, United Kingdom.
  • Gay F; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
  • Minnema MC; Department of Hematology, UMC Utrecht Cancer Centre, Utrecht, The Netherlands.
  • Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
  • Moreau P; Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
  • Cavenagh J; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.
  • Perrot A; Hematology Department, University Hospital, Vandoeuvre Les Nancy, France.
  • Laubach JP; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Krejcik J; Vejle Hospital and University of Southern Denmark, Vejle, Denmark.
  • Ahmadi T; Genmab US Inc., Princeton, NJ, USA.
  • de Boer C; Janssen Biologics, Leiden, The Netherlands.
  • Chen D; Janssen Research & Development, Shanghai, China.
  • Chiu C; Janssen Research & Development, Spring House, PA, USA.
  • Schecter JM; Janssen Research & Development, Raritan, NJ, USA.
  • Richardson PG; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Br J Haematol ; 186(3): e35-e39, 2019 08.
Article em En | MEDLINE | ID: mdl-30931524
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Limite: Female / Humans / Male Idioma: En Revista: Br J Haematol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Dinamarca
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Limite: Female / Humans / Male Idioma: En Revista: Br J Haematol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Dinamarca